[1] Andrica, D., and Rassias, T. Differential and integral inequalities, Cham: Springer, 2019.
[2] Ayala-Hernández, L.E., Gallegos, A., Schucht, P., Murek, M., Pérez-Romasanta, L.,
Belmonte-Beitia, J. and Pérez-García, V.M. Optimal combinations of chemotherapy and
radiotherapy in low-grade gliomas: a mathematical approach, J. Pers. Med., 11(10) (2021),
1036.
[3] Balatif, O., and Rachik, M., and Rachik, Z. Optimal control for multi-input bilinear systems
with an application in cancer chemotherapy, Int. J. Sci. Innov. Math. Res. (IJSIMR), 3
(2015), 22–31.
[4] Benzekry, S., Lamont, C., Beheshti, A., Tracz, A., Ebos, J.M., Hlatky, L. and Hahnfeldt, P.
Classical mathematical models for description and prediction of experimental tumor growth,
PLoS Comput. Biol., 10(8) (2014), e1003800.
[5] Bodnar, M., Vela-Pérez, M. and Tryniecka-Maciek, A. Analyzing the impact of proliferation
and treatment parameters on low-grade glioma growth using mathematical models, Physica
D, 472 (2025), 134491.
[6] Bull, J.A., Mech, F., Quaiser, T., Waters, S.L. and Byrne, H.M. Mathematical modelling
reveals cellular dynamics within tumour spheroids, PLoS Comput. Biol., 16(8) (2020),
e1007961.
[7] Cai, Z., Yang, H., Yu, Z., Su, J., Zhang, J., Ye, Z., Hu, K., Huang, T. and Zhou, H. Efficacy
and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis
of 4 randomized controlled trials, World J. Surg. Oncol., 22(1) (2024), 295.
[8] Carmona-Moreno, F.J., Gallegos, A., Barba-Franco, J.J., Urenda-Cázares, E., Jiménez-
Guerrero, E.V. and Macías-Díaz, J.E. Dynamics analysis of nonlinear differential equation
systems applied to low-grade gliomas and their treatment, Foundations, 5(1) (2025), 6.
[9] Coddington, E.A., and Levinson, N. Theory of ordinary differential equations, New York:
McGraw-Hill, 1955.
[10] Davarian, N., Heydari, A., Hashemi Mehne, S.H. and Heydari, A.A. The investigation of
stability and optimal control of the multigroup Covid-19 epidemic model in Iran, J. Math.
Exten., 19(1) (2025), 1–32.
[11] Diekmann, O., Heesterbeek, J.A.P., and Metz, J.A.J. On the definition and the computa-
tion of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous
populations, J. Math. Biol., 28(4) (1990), 365–382.
[12] Edelstein-Keshet, L. Mathematical models in biology, Philadelphia: SIAM, 2005.
[13] Eisenstein, M. FDA approves first IDH-targeted glioma drug, Nature Portfolio News, 2024.
[14] Fleming, W.H., and Rishel, R.W. Deterministic and stochastic optimal control, New York:
Springer, 2012.
[15] Forst, D.A., Nahed, B.V., Loeffler, J.S. and Batchelor, T.T., Low-grade gliomas, Oncologist,
19(4) (2014), 403–413.
[16] Han, S., Liu, Y., Cai, S.J., Qian, M., Ding, J., Larion, M., Gilbert, M.R. and Yang, C. IDH
mutation in glioma: molecular mechanisms and potential therapeutic targets, Br. J. Cancer,
122(11) (2020), 1580–1589.
[17] Handoko, H., Wahyudi, S.T., Setyawan, A.A. and Kartono, A. A dynamical model of com-
bination therapy applied to glioma, J. Biol. Phys., 48(4) (2022), 439–459.
[18] Hollon, T., Hervey-Jumper, S.L., Sagher, O. and Orringer, D.A. Advances in the surgical
management of low-grade glioma, Semin. Radiat. Oncol., 25(3) (2015), 181–188.
[19] Jaber, T., and Balatif, O. A mathematical model of drug-resistant cancer with cell cycle
structure: stability, optimal control, and cost-effectiveness analysis, Int. J. Dyn. Control,
13(10) (2025), 354.
[20] Jakola, A.S., Skjulsvik, A.J., Myrmel, K.S., Sjåvik, K., Unsgård, G., Torp, S.H., Aaberg,
K., Berg, T., Dai, H.Y., Johnsen, K. and Kloster, R. Surgical resection versus watchful
waiting in low-grade gliomas, Ann. Oncol., 28(8) (2017), 1942–1948.
[21] Khajanchi, S. Stability analysis of a mathematical model for glioma-immune interaction
under optimal therapy, Int. J. Nonlin. Sci. Numer. Simul., 20(3-4) (2019), 269–285.
[22] Khalil, H.K. and Grizzle, J.W. Nonlinear systems, 3rd ed., Upper Saddle River, NJ: Prentice
Hall, 2002.
[23] Kopp, R.E. Pontryagin maximum principle, in: Mathematics in Science and Engineering,
Vol. 5, Amsterdam: Elsevier, (1962), 255–279.
[24] Kurzweil, J. Ordinary differential equations: Introduction to the theory in the real domain,
Amsterdam: Elsevier, 2014.
[25] La Salle, J.P. The Stability of dynamical systems, Philadelphia: SIAM, 1976.
[26] Ledzewicz, U., and Schättler, H. Analysis of a mathematical model for low-grade gliomas
under chemotherapy as a dynamical system, Nonlinear Anal. Real World Appl., 85 (2025),
104344.
[27] Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., Hawkins,
C., Ng, H.K., Pfister, S.M., Reifenberger, G. and Soffietti, R. The 2021 WHO classification
of tumors of the central nervous system: a summary, Neuro Oncol., 23(8) (2021), 1231–1251.
[28] McAsey, M., Mou, L. and Han, W. Convergence of the forward-backward sweep method in
optimal control, Comput. Optim. Appl., 53(1) (2012), 207–226.
[29] McDuff, S.G., Dietrich, J., Atkins, K.M., Oh, K.S., Loeffler, J.S. and Shih, H.A. Radiation
and chemotherapy for high-risk lower grade gliomas: choosing between temozolomide and
PCV, Cancer Med., 9(1) (2020), 3–11.
[30] Mellinghoff, I.K., Van Den Bent, M.J., Blumenthal, D.T., Touat, M., Peters, K.B., Clarke,
J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W.P. and Ducray, F. Vorasidenib in IDH1-
or IDH2-mutant low-grade glioma, N. Engl. J. Med., 389(7) (2023), 589–601.
[31] Minniti, G., Paolini, S., Antonelli, M., Gianno, F., Tini, P., Lanzetta, G., Arcella, A.,
De Pietro, R., Giraffa, M., Capone, L. and Romano, A. Long-term treatment outcomes of
temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2
astrocytoma, J. Neurooncol., 164(2) (2023), 331–339.
[32] Nagumo, M. Über die lage der integralkurven gewöhnlicher differentialgleichungen, Proc.
Phys Math. Soc. Jpn., 24 (1942), 551–559.
[33] Pace, A., Vidiri, A., Galie, E., Carosi, M., Telera, S., Cianciulli, A.M., Canalini, P., Gi-
annarelli, D., Jandolo, B. and Carapella, C.M. Temozolomide chemotherapy for progressive
low-grade glioma: clinical benefits and radiological response, Ann. Oncol., 14(12) (2003),
1722–1726.
[34] Patel, S.H., Bansal, A.G., Young, E.B., Batchala, P.P., Patrie, J.T., Lopes, M.B., Jain, R.,
Fadul, C.E. and Schiff, D. Extent of surgical resection in lower-grade gliomas: differential
impact based on molecular subtype, AJNR Am. J. Neuroradiol., 40(7) (2019), 1149–1155.
[35] Reuvers, M.J., Burgers, V.W., Koekkoek, J.A., Brandsma, D., Compter, A., Kouwenhoven,
M.C., van den Bent, M.J., Frissen, S.A., Husson, O. and van der Graaf, W.T. Aiming at
a moving target the daily life experiences of adolescents and young adults with a low-grade
glioma, Neurooncol. Pract., 12(1) (2025), 113–121.
[36] Ribba, B., Kaloshi, G., Peyre, M., Ricard, D., Calvez, V., Tod, M., Čajavec-Bernard,
B., Idbaih, A., Psimaras, D., Dainese, L. and Pallud, J. A tumor growth inhibition model
for low-grade glioma treated with chemotherapy or radiotherapy, Clin. Cancer Res., 18(18)
(2012), 5071–5080.
[37] Shaw, E.G., Wang, M., Coons, S.W., Brachman, D.G., Buckner, J.C., Stelzer, K.J., Barger,
G.R., Brown, P.D., Gilbert, M.R. and Mehta, M.P. Randomized trial of radiation therapy
plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-
grade glioma: initial results of RTOG 9802, J. Clin. Oncol., 30(25) (2012), 3065–3070.
[38] Spitaels, J., Devriendt, D., Sadeghi, N., Luce, S., De Witte, O., Goldman, S., Mélot, C. and
Lefranc, F. Management of supratentorial recurrent low-grade glioma: a multidisciplinary
experience in 35 adult patients, Oncol. Lett., 14(3) (2017), 2789–2795.
[39] Teng, C., Zhu, Y., Li, Y., Dai, L., Pan, Z., Wanggou, S. and Li, X. Recurrence- and
malignant progression-associated biomarkers in low-grade gliomas and their roles in im-
munotherapy, Front. Immunol., 13 (2022), 899710.
[40] Van den Driessche, P., and Watmough, J. Reproduction numbers and sub-threshold endemic
equilibria for compartmental models of disease transmission, Math. Biosci., 180(1-2) (2002),
29–48.
[41] Wan, Q., Wu, X., Zhou, J., Wu, W., Cao, Y., Sun, C., Li, Z., Gong, Z., Tang, H., Li,
Q. and Chu, J. The hypoxia-associated high-risk cell subpopulation distinctly enhances the
progression of glioma, Adv. Sci., 12(17) (2025), 2416231
